Efficacy of Encorelane in Enhancing Barrier Function and Reducing Aging Signs in Sensitive Skin
Year: 2025
Type: article
Abstract: BACKGROUND: Sensitive skin requires targeted care to improve barrier function, reduce inflammation, and manage neurovascular reactivity. OBJECTIVE: Encorelane, a novel ingredient blend of saccharide isomerate, ribose, and fructooligosaccharides, was evaluated for its efficacy in addressing sensitive skin and visible aging signs. METHODS: In vitro: A 3D epidermal model (EpiKutis) with Sodium Lauryl Sulfate (SLS) induction was used to assess cytokines (interleukin 1α [IL-1α], interleukin 6 [IL-6], interleukin 8 [IL-8], tumor necrosis factor α [TNF-α], prostaglandin E2 [PGE2]) and barrier markers (filaggrin [FLG], loricrin [LOR], transglutaminase 1 [TGM1]). Hydration was examined via aquaporin 3 (AQP3) expression levels. Anti-wrinkle efficacy was tested against UVA/UVB exposure, evaluating collagen synthesis and skin matrix components (Collagen types I, III, IV, VII, XVII, Laminin 5, hyaluronic acid [HA], Chondroitin sulfate [CS]). In vivo: A 6-week double-blind, half-face study in 23 sensitive-skin subjects evaluated the clinical effects of Encorelane versus placebo on repair, redness, firmness, and wrinkles. RESULTS: In vitro: Compared to the control group, Encorelane significantly reduced the levels of IL-1α, TNF-α, IL-6, IL-8, and PGE2 (p < 0.05), and significantly increased the levels of AQP3, FLG, LOR, TGM1, collagen types I, III, IV, VII, XVII, and laminin 5 (p < 0.05). In vivo: Compared to the placebo, Encorelane significantly improved TEWL, R2, F4, and crow's feet wrinkles (p < 0.05). CONCLUSION: Encorelane effectively targets both inflammation and aging signs, supporting its use as a dermocosmetic solution for sensitive, aging-prone skin.
Source: Journal of Cosmetic Dermatology
DOI: 10.1111/jocd.70454
Authors: Lina Wang, Caixia Wang, Liyuan Jiang, Huiping Hu, Yuxuan Wu, Yanan Li, Peiwen Sun
Language: English
Topic: Skin Protection and Aging
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,020
OpenAlex ID: W4414167288